Anika Therapeutics, Inc.
ANIKDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
ANIK Earnings Report
EPS Est: $-0.19 | FQ end 2026-06 | Call: 2026-07-29 15:00:00
How ANIK's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cingal | Phase 3 | Osteoarthritis, Knee | - | - |
Triamcinolone Hexacetonide | Phase 3 | Knee Osteoarthritis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Anika Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Anika Therapeutics, Inc.'s (ANIK) pipeline across Phase 3. Its lead program is Cingal (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Anika Therapeutics, Inc.'s next FDA catalyst?→
Anika Therapeutics, Inc.'s (ANIK) next tracked catalyst is a Earnings expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANIK biotech catalysts?→
Add ANIK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Anika Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.